A randomized, double-blind, placebo-controlled Phase III clinical trial to assess the efficacy, safety, and tolerability of Maridebart Cafraglutide in adult patients without type 2 diabetes who are obese or overweight
Résumé de l'étude
This is a Phase III study, the early development phase of drugs for humans. The researchers will evaluate and provide information on how well Maridebart Cafraglutide works and how well it is tolerated compared to placebo in a person for the treatment of obesity or overweight, and whether it causes side effects. The study lasts for each participant 84 weeks and includes a pre-screening period of up to 4 weeks, a 72-week treatment period, and a safety follow-up visit 12 weeks after the last dose of Maridebart Cafraglutide. The study will include men and women who are at least 18 years old and suffer from obesity or overweight, having a BMI of ≥ 30 kg/m2 or a BMI of ≥ 27 to < 30 kg/m2, and who have had at least one unsuccessful attempt to lose weight through diet and exercise in the opinion of the investigator. Participants who have type 1 or type 2 diabetes mellitus or who have had (or plan to have during the study) a surgical or endoscopic procedure for the treatment of overweight are not allowed to participate in the study. Participants who have taken or are taking unauthorized medications as part of the study are not allowed to participate.
(BASEC)
Intervention étudiée
Participants will receive either Maridebart Cafraglutide (3 different doses) or a placebo as a subcutaneous injection.
(BASEC)
Maladie en cours d'investigation
Obesity or overweight
(BASEC)
- Age: at least 18 years - Body Mass Index ≥ 30 kg/m2 or Body Mass Index ≥ 27 to < 30 kg/m2 with at least one of the following weight-related conditions: Hypertension Dyslipidemia Sleep apnea Cardiovascular diseases - At least one unsuccessful attempt to lose weight through diet and exercise (BASEC)
Critères d'exclusion
- Overweight induced by other endocrinological disorders - Weight change of > 5 kg within 90 days prior to the pre-screening period of the study - Type 1 or type 2 diabetes mellitus or other types of diabetes (except for gestational diabetes in the past) (BASEC)
Lieu de l’étude
Bâle, Genève, St-Gall, Zurich
(BASEC)
Sponsor
Amgen Switzerland AG Amgen Inc.
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Prof. Dr. med. Katharina Timper
+41 61 207 07 73
katharina.timper@clutterusb.chUniversitätsspital Basel Endokrinologie, Diabetologie und Metabolismus
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Ethikkommission Nordwest- und Zentralschweiz EKNZ
(BASEC)
Date d'approbation du comité d'éthique
03.04.2025
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-1) (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible